These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 21063134)

  • 1. Treatment efficacy/safety and prognostic factors in patients with advanced biliary tract cancer receiving gemcitabine monotherapy: an analysis of 100 cases.
    Suzuki E; Furuse J; Ikeda M; Okusaka T; Nakachi K; Mitsunaga S; Ueno H; Morizane C; Kondo S; Shimizu S; Kojima Y; Hagihara A
    Oncology; 2010; 79(1-2):39-45. PubMed ID: 21063134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of gemcitabine monotherapy for patients with advanced biliary tract cancer.
    Yokoyama T; Yoshida H; Makino H; Maruyama H; Suzuki S; Matsutani T; Matsushita A; Hirakata A; Sasajima K; Uchida E
    J Nippon Med Sch; 2012; 79(3):204-12. PubMed ID: 22791122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
    Abdel-Rahman O; Elsayed Z; Elhalawani H
    Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011746. PubMed ID: 29624208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A retrospective study of S-1 monotherapy as second-line treatment for patients with advanced biliary tract cancer.
    Kobayashi S; Ueno M; Ohkawa S; Andou T; Kameda R; Yamamoto N; Morinaga S
    Jpn J Clin Oncol; 2012 Sep; 42(9):800-6. PubMed ID: 22826349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and biomarker analysis of nivolumab plus gemcitabine and cisplatin in patients with unresectable or metastatic biliary tract cancers: results from a phase II study.
    Feng K; Liu Y; Zhao Y; Yang Q; Dong L; Liu J; Li X; Zhao Z; Mei Q; Han W
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32487569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine.
    Sasaki T; Isayama H; Nakai Y; Mizuno S; Yamamoto K; Yagioka H; Yashima Y; Kawakubo K; Kogure H; Togawa O; Matsubara S; Ito Y; Sasahira N; Hirano K; Tsujino T; Toda N; Tada M; Omata M; Koike K
    Invest New Drugs; 2012 Apr; 30(2):708-13. PubMed ID: 20924641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of single-agent gemcitabine in patients with advanced biliary tract cancer.
    Okusaka T; Ishii H; Funakoshi A; Yamao K; Ohkawa S; Saito S; Saito H; Tsuyuguchi T
    Cancer Chemother Pharmacol; 2006 May; 57(5):647-53. PubMed ID: 16142487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-agent gemcitabine in the treatment of advanced biliary tract cancers: a phase II study.
    Park JS; Oh SY; Kim SH; Kwon HC; Kim JS; Jin-Kim H; Kim YH
    Jpn J Clin Oncol; 2005 Feb; 35(2):68-73. PubMed ID: 15709089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A retrospective study of chemotherapy with cisplatin plus gemcitabine after the failure of gemcitabine monotherapy for biliary tract cancer.
    Kameda R; Ando T; Kobayashi S; Ueno M; Ohkawa S
    Jpn J Clin Oncol; 2013 Jun; 43(6):636-40. PubMed ID: 23619988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer.
    Suzuki E; Ikeda M; Okusaka T; Nakamori S; Ohkawa S; Nagakawa T; Boku N; Yanagimoto H; Sato T; Furuse J
    Cancer Chemother Pharmacol; 2013 May; 71(5):1141-6. PubMed ID: 23525694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single-agent gemcitabine in elderly patients with unresectable biliary tract cancer.
    Kuriyama H; Kawana K; Taniguchi R; Jono F; Sakai E; Okubo H; Suzuki H; Kobayashi S; Murata Y; Inamori M; Hata Y; Nakajima A
    Hepatogastroenterology; 2011; 58(105):26-30. PubMed ID: 21510281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study.
    Yoo C; Kim KP; Jeong JH; Kim I; Kang MJ; Cheon J; Kang BW; Ryu H; Lee JS; Kim KW; Abou-Alfa GK; Ryoo BY
    Lancet Oncol; 2021 Nov; 22(11):1560-1572. PubMed ID: 34656226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer.
    Penz M; Kornek GV; Raderer M; Ulrich-Pur H; Fiebiger W; Lenauer A; Depisch D; Krauss G; Schneeweiss B; Scheithauer W
    Ann Oncol; 2001 Feb; 12(2):183-6. PubMed ID: 11300321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic predictive values of gemcitabine sensitivity-related gene products for unresectable or recurrent biliary tract cancer treated with gemcitabine alone.
    Murata A; Amano R; Yamada N; Kimura K; Yashiro M; Nakata B; Hirakawa K
    World J Surg Oncol; 2013 May; 11():117. PubMed ID: 23710668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and effectiveness of gemcitabine in 260 patients with biliary tract cancer in a Japanese clinical practice based on post-marketing surveillance in Japan.
    Okubo S; Nishiuma S; Kobayashi N; Taketsuna M; Taniai H
    Jpn J Clin Oncol; 2012 Nov; 42(11):1043-53. PubMed ID: 23042772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of gemcitabine-based chemotherapies in biliary tract cancer: a meta-analysis.
    Liu H; Zhang QD; Li ZH; Zhang QQ; Lu LG
    World J Gastroenterol; 2014 Dec; 20(47):18001-12. PubMed ID: 25548500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive factors of the treatment outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy.
    Suzuki Y; Kan M; Kimura G; Umemoto K; Watanabe K; Sasaki M; Takahashi H; Hashimoto Y; Imaoka H; Ohno I; Mitsunaga S; Ikeda M
    J Gastroenterol; 2019 Mar; 54(3):281-290. PubMed ID: 30298469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-agent gemcitabine in elderly patients with unresectable biliary tract cancer.
    Kuriyama H; Kawana K; Taniguchi R; Jono F; Sakai E; Ohubo H; Suzuki H; Kobayashi S; Murata Y; Inamori M; Hata Y; Nahajima A
    Hepatogastroenterology; 2011; 58(106):270-4. PubMed ID: 21661380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study.
    Lee J; Park SH; Chang HM; Kim JS; Choi HJ; Lee MA; Jang JS; Jeung HC; Kang JH; Lee HW; Shin DB; Kang HJ; Sun JM; Park JO; Park YS; Kang WK; Lim HY
    Lancet Oncol; 2012 Feb; 13(2):181-8. PubMed ID: 22192731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PICCA study: panitumumab in combination with cisplatin/gemcitabine chemotherapy in KRAS wild-type patients with biliary cancer-a randomised biomarker-driven clinical phase II AIO study.
    Vogel A; Kasper S; Bitzer M; Block A; Sinn M; Schulze-Bergkamen H; Moehler M; Pfarr N; Endris V; Goeppert B; Merx K; Schnoy E; Siveke JT; Michl P; Waldschmidt D; Kuhlmann J; Geissler M; Kahl C; Evenkamp R; Schmidt T; Kuhlmann A; Weichert W; Kubicka S
    Eur J Cancer; 2018 Mar; 92():11-19. PubMed ID: 29413685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.